Abstract
MLN4924 (1), which is in clinical trials as an anticancer agent, was stereoselectively synthesized from d-ribose via a route involving stereoselective reduction, regioselective cleavage of an isopropylidene moiety, and selective displacement of a cyclic sulfate moiety as key steps.
Original language | English |
---|---|
Pages (from-to) | 3557-3561 |
Number of pages | 5 |
Journal | Journal of Organic Chemistry |
Volume | 76 |
Issue number | 9 |
DOIs | |
State | Published - 6 May 2011 |